Archaeosomes made of Halorubrum tebenquichensetotal polar lipids: a new source of adjuvancy

Gonzalez, Raul O; Higa, Leticia Herminia; Cutrullis, Romina Andrea; Bilen, Marcos; Morelli, Irma Susana; Roncaglia, Diana I.; Corral, Ricardo S.; Morilla, María José; Petray, Patricia; Romero, Eder Lilia

doi:10.1186/1472-6750-9-71

Cited by 37 publications

(27 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These reports are in accordance with our records. Gonzalez et al [17] reported same results for ARC. The cytotoxicity effect of the archaeosomal paclitaxel formulation probed by MTT assay and as a result the archaeosomal formulation without any drug indicated a negligible cytotoxicity effect on MCF-7.…”

Section: Discussionsupporting

confidence: 74%

Archaeosome: As New Drug Carrier for Delivery of Paclitaxel to Breast Cancer

et al. 2013

View full text Add to dashboard Cite

In the present study, paclitaxel was archaeosomed to reduce side effects and improve its therapeutic index. Carriers have made a big evolution in treatment of many diseases in recent years. Lipid carriers are of special importance among carriers. Archaeosome is one of the lipid carriers. Paclitaxel is one of the drugs used to treat breast cancer which has some unwanted side effects despite its therapeutic effects. Archaeosomes were extracted from methanogenic archi bacteria and synthesized with a certain ratio of paclitaxel in PBS. The mean diameter of archaeosomal paclitaxel was measured by Zeta sizer instrument, Drug releasing of archaeosomal paclitaxel was examined within 26 h which results showed that the most drug releasing occurs during first 3 h. The cytotoxicity effect of archaeosomal paclitaxel on breast cancer's cell line was evaluated by MTT assay which results showed that the cytotoxicity effect of archaeosomal paclitaxel on breast cancer's cell line is more than that of the standard paclitaxel formulation. The results indicated that new drug delivery of paclitaxel using archaeosome, increases the therapeutic index of the drug.

show abstract

Section: Discussionsupporting

confidence: 74%

Archaeosome: As New Drug Carrier for Delivery of Paclitaxel to Breast Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Immunization of mice with ovalbumin (OVA) entrapped in all archaeosomes lipid compositions evoked a primary (day 10) splenic CTL response indicating processing for MHC class I presentation. Polar lipid compositions from halophilic archaea were very potent to adjuvant this early CTL response (Gonzalez et al, 2009). The lytic units reduced significantly by weeks 6-7.…”

Section: Applications Of Archaeosome Formulationsmentioning

confidence: 95%

Archaeosomes: an excellent carrier for drug and cell delivery

et al. 2015

View full text Add to dashboard Cite

Archaeosomes as liposomes made with one or more ether lipids that are unique to the domain of Archaeobacteria, found in Archaea constitute a novel family of liposome. Achaean-type lipids consist of archaeol (diether) and/or caldarchaeol (tetraether) core structures. Archaeosomes can be produced using standard procedures (hydrated film submitted to sonication, extrusion and detergent dialysis) at any temperature in the physiological range or lower, therefore making it possible to encapsulate thermally stable compounds. Various physiological as well as environmental factors affect its stability. Archaeosomes are widely used as drug delivery systems for cancer vaccines, Chagas disease, proteins and peptides, gene delivery, antigen delivery and delivery of natural antioxidant compounds. In this review article, our major aim was to explore the applications of this new carrier system in pharmaceutical field.

show abstract

“…Therefore, in this work, a commercial hydrophobic ZnPc was loaded into TPAs containing liposomes, and its in vitro leishmanicidal activity was compared to that of ZnPc loaded in UDLs on macrophages infected with L. braziliensis amastigotes. 37 Cultures were monitored by absorbance at 660 nm and harvested in the late stationary phase for storage as frozen cell pastes.…”

Section: Introductionmentioning

confidence: 99%

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes

Perez

Casasco

Schilrreff

et al. 2014

IJN

Self Cite

View full text Add to dashboard Cite

In this work, the in vitro anti-Leishmania activity of photodynamic liposomes made of soybean phosphatidylcholine, sodium cholate, total polar archaeolipids (TPAs) extracted from the hyperhalophile archaea Halorubrum tebenquichense and the photosensitizer zinc phthalocyanine (ZnPcAL) was compared to that of ultradeformable photodynamic liposomes lacking TPAs (ZnPcUDLs). We found that while ZnPcUDLs and ZnPcALs (130 nm mean diameter and −35 mV zeta potential) were innocuous against promastigotes, a low concentration (0.01 µM ZnPc and 7.6 µM phospholipids) of ZnPcALs irradiated at a very low-energy density (0.2 J/cm 2 ) eliminated L. braziliensis amastigotes from J774 macrophages, without reducing the viability of the host cells. In such conditions, ZnPcALs were harmless for J774 macrophages, HaCaT keratinocytes, and bone marrow-derived dendritic cells. Therefore, topical photodynamic treatment would not likely affect skin-associated lymphoid tissue. ZnPcALs were extensively captured by macrophages, but ZnPcUDLs were not, leading to 2.5-fold increased intracellular delivery of ZnPc than with ZnPcUDLs. Despite mediating low levels of reactive oxygen species, the higher delivery of ZnPc and the multiple (caveolin-and clathrin-dependent plus phagocytic) intracellular pathway followed by ZnPc would have been the reason for the higher antiamastigote activity of ZnPcALs. The leishmanicidal activity of photodynamic liposomal ZnPc was improved by TPA-containing liposomes.

show abstract

Archaeosomes made of Halorubrum tebenquichensetotal polar lipids: a new source of adjuvancy

Cited by 37 publications

References 62 publications

Archaeosome: As New Drug Carrier for Delivery of Paclitaxel to Breast Cancer

Archaeosome: As New Drug Carrier for Delivery of Paclitaxel to Breast Cancer

Archaeosomes: an excellent carrier for drug and cell delivery

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes

Contact Info

Product

Resources

About